XML 65 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Tables)
 12 Months Ended
Jun. 30, 2017
Segment Reporting [Abstract]  
Net Revenue and Segment EBITDA
The following tables include net revenue and Segment EBITDA for each of the Company's reporting segments during the fiscal years ended June 30, 2017, June 30, 2016, and June 30, 2015:
(Dollars in millions)
Fiscal Year Ended  
 June 30,
2017
 
2016
 
2015
Softgel Technologies
 
 
 
 
 
Net revenue
$
855.3

 
$
775.0

 
$
787.5

Segment EBITDA
$
190.5

 
$
163.8

 
$
173.6

Drug Delivery Solutions
 
 
 
 
 
Net revenue
910.1

 
806.4

 
798.3

Segment EBITDA
242.4

 
215.2

 
230.7

Clinical Supply Services
 
 
 
 
 
Net revenue
348.8

 
307.5

 
288.4

Segment EBITDA
54.9

 
53.2

 
56.7

Inter-segment revenue elimination
(38.8
)
 
(40.8
)
 
(43.4
)
Unallocated costs (1)
(115.6
)
 
(57.9
)
 
(100.8
)
Combined Total
 
 
 
 
 
Net revenue
$
2,075.4

 
$
1,848.1

 
$
1,830.8

 
 
 
 
 
 
EBITDA from continuing operations
$
372.2

 
$
374.3

 
$
360.2


(1)
Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:
(Dollars in millions)
Fiscal Year Ended  
 June 30,
2017
 
2016
 
2015
Impairment charges and gain/(loss) on sale of assets
$
(9.8
)
 
$
(2.7
)
 
$
(4.7
)
Equity compensation
(20.9
)
 
(10.8
)
 
(9.0
)
Restructuring and other items (2)
(33.5
)
 
(27.2
)
 
(27.2
)
Noncontrolling interest
—

 
0.3

 
1.9

Other income/(expense), net (3)
(8.5
)
 
15.6

 
(42.4
)
Non-allocated corporate costs, net
(42.9
)
 
(33.1
)
 
(19.4
)
Total unallocated costs
$
(115.6
)
 
$
(57.9
)
 
$
(100.8
)
(2)
Segment results do not include restructuring and certain acquisition-related costs.
(3)
Refer to Note 13 for details.
Reconciliation of earnings/(loss) from continuing operations to EBITDA
Provided below is a reconciliation of earnings/(loss) from continuing operations to EBITDA from continuing operations:
(Dollars in millions)
Fiscal Year Ended  
 June 30,
2017
 
2016
 
2015
Earnings/(loss) from continuing operations
$
109.8

 
$
111.2

 
$
210.2

Depreciation and amortization
146.5

 
140.6

 
140.8

Interest expense, net
90.1

 
88.5

 
105.0

Income tax (benefit)/expense
25.8

 
33.7

 
(97.7
)
Noncontrolling interest
—

 
0.3

 
1.9

EBITDA from continuing operations
$
372.2

 
$
374.3

 
$
360.2
Total Assets for Each Segment and Reconciling in Consolidated Financial Statements
The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the Consolidated Financial Statements:
(Dollars in millions)
June 30, 
 2017
 
June 30, 
 2016
Assets
 
 
 
Softgel Technologies
$
1,631.8

 
$
1,446.4

Drug Delivery Solutions
1,639.0

 
1,475.7

Clinical Supply Services
596.2

 
578.9

Corporate and eliminations
(412.7
)
 
(409.9
)
Total assets
$
3,454.3

 
$
3,091.1
Representation of depreciation and amortization expense and capital expenditure by segment
Depreciation and Amortization Expense
(Dollars in millions)
Fiscal Year Ended  
 June 30,
2017
 
2016
 
2015
Softgel Technologies
$
38.4

 
$
36.7

 
$
42.8

Drug Delivery Solutions
75.3

 
72.9

 
66.9

Clinical Supply Services
18.7

 
21.1

 
24.1

Corporate
14.1

 
9.9

 
7.0

Total depreciation and amortization expense
$
146.5

 
$
140.6

 
$
140.8
Capital Expenditures by Segment
Capital Expenditures
(Dollars in millions)
Fiscal Year Ended  
 June 30,
2017
 
2016
 
2015
Softgel Technologies
$
27.6

 
$
20.6

 
$
29.6

Drug Delivery Solutions
83.5

 
92.4

 
86.2

Clinical Supply Services
7.2

 
5.1

 
6.4

Corporate
21.5

 
21.5

 
18.8

Total capital expenditure
$
139.8

 
$
139.6

 
$
141.0
Presentation of revenue and long-lived assets by geographic area
The following table presents revenue and long-lived assets by geographic area:  
 
Net Revenue
 
Long-Lived Assets(1)
(Dollars in millions)
Fiscal Year Ended  
 June 30,
 
 
 
 
2017
 
2016
 
2015
 
June 30, 
 2017
 
June 30, 
 2016
United States
$
996.4

 
$
858.6

 
$
799.3

 
$
588.0

 
$
538.9

Europe
797.4

 
733.2

 
795.4

 
281.6

 
280.2

International Other
345.0

 
313.5

 
268.6

 
126.3

 
86.7

Eliminations
(63.4
)
 
(57.2
)
 
(32.5
)
 
—

 
—

Total
$
2,075.4

 
$
1,848.1

 
$
1,830.8

 
$
995.9

 
$
905.8

(1)
Long-lived assets include property and equipment, net of accumulated depreciation.